YOLFTbeta
Original BioMedicals Co., Ltd.

Original BioMedicals Co., Ltd.

6483 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

13.85TWD-0.40 (-2.81%)

Price History

Full chart

Market Stats

Previous Close14.25
Open14.25
Day Range13.40 – 14.25
52-Week Range11.00 – 20.00
Volume347.96K
Market Cap878.53M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.54
Dividend Yield0.00%
Beta0.22
50-Day Avg13.30
200-Day Avg14.19

About

Original BioMedicals Co., Ltd. engages in the development of drugs in Taiwan. The company develops OBM-A01, a radiation injury prevention and therapeutic drug for the treatment of acute radiation injuries, including nuclear radiation and solar radiation exposure in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for the treatment of iron deficiency. It also provides NE (vitamin C+E) and NE Butorphanol, as well as technical services. Original BioMedicals Co., Ltd. was incorporated in 2011 and is based in Tainan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Cliff C. Wang Ph.D.
  • Employees25
  • HeadquartersNo. 9, Nanke 2nd Road, Tainan City, Taiwan, 744092, Taiwan
  • Websitehttps://i-obm.com

Leadership

  • Dr. Cliff C. Wang Ph.D.CEO, CRO & Director
  • Lawrence H. T. TangChief Financial Officer
  • Hsiao-Pao YenCOO & Director
  • Mr. Duncan Chen MSCTO & Director
  • Ms. Cecilia HungDirector of Development
  • Dr. Alan Liss Ph.D.Senior Vice President · b. 1948
  • Gan Xiao PingHead of Clinical Research Department

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---107.00K43.00K0381.00K
Growth (%)-----59.81%-100.00%-
Cost of Revenue-11.73M8.61M12.00K8.00K8.40M75.00K
Gross Profit--11.73M-8.61M95.00K35.00K-8.40M306.00K
Gross Margin---88.79%81.40%-80.31%
Operating Expense-22.01M24.05M40.27M59.30M69.93M104.90M
Operating Income-38.94M-33.74M-32.66M-40.18M-59.26M-78.33M-104.60M
Operating Margin----37547.66%-137818.60%--27453.02%
EBITDA-25.77M-21.45M-23.88M-31.20M-49.83M-65.73M-92.09M
EBITDA Margin----29156.07%-115874.42%--24169.82%
Net Income-37.65M-34.75M-33.88M-40.28M-59.66M-75.00M-101.51M
Net Income Margin----37642.06%-138746.51%--26643.04%
R&D26.36M12.30M20.74M22.91M24.71M33.05M47.26M
R&D as % of Total Revenue---21412.15%57467.44%-12403.41%
Interest Expense-1.56M1.39M1.20M1.10M868.00K590.00K
Interest Expense % of Total Revenue---1117.76%2553.49%-154.86%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets93.86M67.40M137.37M98.04M370.63M279.37M183.94M
Total Liabilities33.37M29.44M28.26M28.86M42.07M24.12M26.10M
Total Equity60.49M37.97M109.11M69.17M328.57M255.25M157.84M
Cash22.82M8.10M8.46M13.98M228.68M151.45M133.85M
Total Debt23.61M23.61M20.66M19.89M16.24M11.98M-
Net Debt797.00K12.56M9.06M5.91M-212.44M-139.47M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-26.39M-23.94M-24.93M-30.42M-29.50M-84.11M-96.01M
Investing Cash Flow4.50M--76.77M39.28M-64.29M8.22M-
Financing Cash Flow18.78M9.23M102.07M-3.35M308.49M-1.34M-
Capital Expenditure001.92M467.00K311.00K1.84M949.00K
Free Cash Flow-26.39M-23.94M-26.86M-30.89M-29.81M-85.95M-96.96M
FCF to OCF100.00%100.00%107.72%101.54%101.05%102.19%100.99%

Key Statistics & Ratios

Market Cap878.53M
Enterprise Value793.53M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2411.05
Price / Book7.71
EPS-1.54
Book Value1.66
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-99.31M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-63.64%
Return on Assets-35.35%
Shares Outstanding66.81M
Shares Float55.27M
Beta0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%